184 related articles for article (PubMed ID: 27693529)
1. Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance.
Christiansen MT; Hullegie SJ; Schutten M; Einer-Jensen K; Tutill HJ; Breuer J; Rijnders BJA
Clin Microbiol Infect; 2017 Feb; 23(2):123.e1-123.e4. PubMed ID: 27693529
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
[TBL] [Abstract][Full Text] [Related]
3. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China.
Zhou K; Liang Z; Wang C; Hu F; Ning C; Lan Y; Tang X; Tucker JD; Cai W
PLoS One; 2016; 11(6):e0157438. PubMed ID: 27341031
[TBL] [Abstract][Full Text] [Related]
4. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC
Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
[TBL] [Abstract][Full Text] [Related]
6. Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failure.
Jagjit Singh GK; Kaye S; Abbott JC; Boesecke C; Rockstroh J; McClure MO; Nelson M
HIV Clin Trials; 2018 Apr; 19(2):46-51. PubMed ID: 29493385
[TBL] [Abstract][Full Text] [Related]
7. Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform.
Gaspareto KV; Ribeiro RM; de Mello Malta F; Gomes-Gouvêa MS; Muto NH; Romano CM; Mendes-Correa MC; Carrilho FJ; Sabino EC; Rebello Pinho JR
Antivir Ther; 2016; 21(8):653-660. PubMed ID: 27314166
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
[TBL] [Abstract][Full Text] [Related]
9. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
10. Performance assessment of a fully automated deep sequencing platform for HCV resistance testing.
Rodriguez C; Mercier-Darty M; Soulier A; Poiteau L; Wlassow M; Fourati S; Hézode C; Pawlotsky JM; Chevaliez S
Antivir Ther; 2019; 24(6):417-423. PubMed ID: 31112134
[TBL] [Abstract][Full Text] [Related]
11. Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.
Franco S; Tural C; Nevot M; Moltó J; Rockstroh JK; Clotet B; Martinez MA
Gastroenterology; 2014 Sep; 147(3):599-601.e1. PubMed ID: 24859204
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
[TBL] [Abstract][Full Text] [Related]
13. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
16. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.
Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G
Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164
[TBL] [Abstract][Full Text] [Related]
19. The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
Newsum AM; Ho CK; Lieveld FI; van de Laar TJ; Koekkoek SM; Rebers SP; van der Meer JT; Wensing AM; Boland GJ; Arends JE; van Erpecum KJ; Prins M; Molenkamp R; Schinkel J
AIDS; 2017 Jan; 31(1):105-112. PubMed ID: 27898592
[TBL] [Abstract][Full Text] [Related]
20. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.
Welzel TM; Bhardwaj N; Hedskog C; Chodavarapu K; Camus G; McNally J; Brainard D; Miller MD; Mo H; Svarovskaia E; Jacobson I; Zeuzem S; Agarwal K
J Hepatol; 2017 Aug; 67(2):224-236. PubMed ID: 28343981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
